Effect of Recombinant Human Granulocyte Colony‐Stimulating Factor on Pregnancy Outcomes in Patients With Recurrent Pregnancy Loss: A Single‐Center Retrospective Study
American Journal of Reproductive Immunology · 2026-05 · 95 (5)
DOI: 10.1111/aji.70248 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 29.04.2026. Verfasst von Luming Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Longxi County Traditional Chinese Medicine Hospital, Dingxi, China. Hauptthemen laut MEDLINE: Granulocyte Colony-Stimulating Factor, Abortion, Habitual. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Science Foundation of Lanzhou University Second Hospital.
Abstract (Originalsprache)
Objective
This study aims to explore how recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) impacts pregnancy outcomes among patients with recurrent pregnancy loss (RPL), especially the effects of different rhG‐CSF administration types on these outcomes.
Methods
This retrospective cohort study analyzed 504 RPL patients treated at the Lanzhou University Second Hospital, including 291 in the treatment group (receiving rhG‐CSF) and 213 in the control group. Potential confounding factors were adjusted by Propensity Score Matching (PSM) and Inverse Probability of Treatment Weighting (IPTW). Logistic regression was employed to assess the association between rhG‐CSF and pregnancy outcomes. Additionally, exploratory subgroup analysis was performed based on different rhG‐CSF administration types (short‐acting, long‐acting, and sequential therapy).
Results
Overall, rhG‐CSF treatment did not significantly improve the rates of live births (OR = 1.259, 95% CI: 0.771–2.062, p = 0.357), preterm births (OR = 1.095, 95% CI: 0.304–6.143, p = 0.917), or neonatal unit admissions (OR = 1.123, 95% CI: 0.205–7.511, p = 0.898). However, exploratory subgroup analysis revealed that short‐acting rhG‐CSF was linked to a lower live birth rate (LBR) (aOR = 0.476, 95% CI: 0.224–0.971), while sequential therapy significantly increased LBRs (aOR = 2.417, 95% CI: 1.384–4.268). Further analysis showed that there were no significant differences in the rates of preterm birth and neonatal unit admissions among different groups.
Conclusion
Although rhG‐CSF showed no significant overall benefit for pregnancy outcomes in RPL patients, exploratory subgroup analyses revealed divergent effects based on administration types. While a potential negative association was observed with short‐acting rhG‐CSF and a positive impact with sequential therapy, these subgroup‐specific findings should be interpreted with caution and require validation in larger, dedicated prospective cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Longxi County Traditional Chinese Medicine Hospital, Dingxi, China.
- Department of Reproductive Medicine, Lanzhou University Second Hospital, Lanzhou, China.
ORCID-Profile: Fangxiang Mu, Hui Yao, Fang Wang
Förderung
- Science Foundation of Lanzhou University Second Hospital
Zitieren
APA
Chen, L., Mu, F., Yao, H., & Wang, F. (2026). Effect of Recombinant Human Granulocyte Colony‐Stimulating Factor on Pregnancy Outcomes in Patients With Recurrent Pregnancy Loss: A Single‐Center Retrospective Study. American Journal of Reproductive Immunology, 95(5). https://doi.org/10.1111/aji.70248
Vancouver
Chen L, Mu F, Yao H, Wang F. Effect of Recombinant Human Granulocyte Colony‐Stimulating Factor on Pregnancy Outcomes in Patients With Recurrent Pregnancy Loss: A Single‐Center Retrospective Study. American Journal of Reproductive Immunology. 2026;95(5). doi:10.1111/aji.70248
BibTeX
@article{Chen2026,
author = {Chen, Luming and Mu, Fangxiang and Yao, Hui and Wang, Fang},
title = {Effect of Recombinant Human Granulocyte Colony‐Stimulating Factor on Pregnancy Outcomes in Patients With Recurrent Pregnancy Loss: A Single‐Center Retrospective Study},
journal = {American Journal of Reproductive Immunology},
year = {2026},
volume = {95},
number = {5},
doi = {10.1111/aji.70248}
}
EUVIMED